Stockreport

Axovant Reports Results of Exploratory Phase 2 Clinical Study of Nelotanserin in Lewy Body Dementia Patients Experiencing REM Sleep Behavior Disorder

Axon Enterprise, Inc.  (AXON) 
Last axon enterprise, inc. earnings: 2/7 04:15 pm Check Earnings Report
US:NYSE Investor Relations: investors.axovant.com/investors/sec-filings
PDF Primary efficacy endpoint assessed by sleep laboratory video assessment was not metAxovant is discontinuing clinical development of nelotanserin  BASEL, Switzerland, D [Read more]